Life Care News
A Hope Of True Information

Generation Bio to Participate in the BMO Biopharma


CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines, which will take place virtually on Tuesday, March 28th at 10:00 a.m. ET.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit 

Investors and Media Contact
Maren Killackey
Generation Bio

- Advertisement -

Get real time updates directly on you device, subscribe now.